BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15186837)

  • 1. Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases.
    Asano T; Yoshikawa T; Usui T; Yamamoto H; Yamamoto Y; Uehara Y; Nakamura H
    Bioorg Med Chem; 2004 Jul; 12(13):3529-42. PubMed ID: 15186837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of benzamides and benzamidines: structural requirement of a pyrimidine ring for inhibition of EGFR tyrosine kinase.
    Asano T; Yoshikawa T; Nakamura H; Uehara Y; Yamamoto Y
    Bioorg Med Chem Lett; 2004 May; 14(9):2299-302. PubMed ID: 15081028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benzamide and Benzamidine Compounds as New Inhibitors of Urokinasetype Plasminogen Activators.
    Kuş C; Özer E; Korkmaz Y; Yurtcu E; Dağalp R
    Mini Rev Med Chem; 2018; 18(20):1753-1758. PubMed ID: 30112993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors.
    Mao Y; Zhu W; Kong X; Wang Z; Xie H; Ding J; Terrett NK; Shen J; Shen J
    Bioorg Med Chem; 2013 Jun; 21(11):3090-104. PubMed ID: 23602524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.
    Horio T; Hamasaki T; Inoue T; Wakayama T; Itou S; Naito H; Asaki T; Hayase H; Niwa T
    Bioorg Med Chem Lett; 2007 May; 17(10):2712-7. PubMed ID: 17376680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases.
    Lin J; Shen W; Xue J; Sun J; Zhang X; Zhang C
    Eur J Med Chem; 2012 Sep; 55():39-48. PubMed ID: 22818848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
    Hu M; Ye W; Li J; Zhong G; He G; Xu Q; Zhang Y
    Chem Biol Drug Des; 2015 Mar; 85(3):280-9. PubMed ID: 24954438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation.
    Li Z; Hosoi Y; Cai K; Tanno Y; Matsumoto Y; Enomoto A; Morita A; Nakagawa K; Miyagawa K
    Biochem Biophys Res Commun; 2006 Mar; 341(2):363-8. PubMed ID: 16414009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase.
    Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM
    Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
    Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
    Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
    Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM
    J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluation of aminoboronic acids as growth-factor receptor inhibitors of EGFR and VEGFR-1 tyrosine kinases.
    Asano T; Nakamura H; Uehara Y; Yamamoto Y
    Chembiochem; 2004 Apr; 5(4):483-90. PubMed ID: 15185372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active site mapping of trypsin, thrombin and matriptase-2 by sulfamoyl benzamidines.
    Dosa S; Stirnberg M; Lülsdorff V; Häußler D; Maurer E; Gütschow M
    Bioorg Med Chem; 2012 Nov; 20(21):6489-505. PubMed ID: 23026080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC-family tyrosine kinases in wound- and ligand-induced epidermal growth factor receptor activation in human corneal epithelial cells.
    Xu KP; Yin J; Yu FS
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2832-9. PubMed ID: 16799022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of Src protein tyrosine kinase by analogues of 5-S-glutathionyl-beta-alanyl-L-dopa.
    Zheng ZB; Nagai S; Iwanami N; Kobayashi A; Hijikata M; Natori S; Sankawa U
    Chem Pharm Bull (Tokyo); 1998 Dec; 46(12):1950-1. PubMed ID: 9880915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
    Leung EL; Tam IY; Tin VP; Chua DT; Sihoe AD; Cheng LC; Ho JC; Chung LP; Wong MP
    Mol Cancer Res; 2009 Jun; 7(6):923-32. PubMed ID: 19491201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
    Barchéchath S; Williams C; Saade K; Lauwagie S; Jean-Claude B
    Chem Biol Drug Des; 2009 Apr; 73(4):380-7. PubMed ID: 19291100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.